Nephros Stock Analysis

Nephros Stock Analysis Notes

About 13.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 2.0. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Nephros recorded a loss per share of 0.09. The entity last dividend was issued on the 10th of July 2019. The firm had 1:9 split on the 10th of July 2019. Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey. Nephros operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 34 people. To find out more about Nephros contact Daron Evans at 201 343 5202 or learn more at https://www.nephros.com.

Nephros Investment Alerts

Nephros Upcoming and Recent Events

Nephros Largest EPS Surprises

View All Earnings Estimates

Nephros Stock Institutional Investors

Note, although Nephros' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Nephros Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.34 M.

Nephros Profitablity

The company has Profit Margin (PM) of (0.09) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.1) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.1.

Management Efficiency

Nephros has return on total asset (ROA) of (0.0796) % which means that it has lost $0.0796 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1561) %, meaning that it created substantial loss on money invested by shareholders. Nephros' management efficiency ratios could be used to measure how well Nephros manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.16. The current Return On Capital Employed is estimated to decrease to -0.17. As of now, Nephros' Asset Turnover is increasing as compared to previous years.

Technical Drivers

As of the 1st of December, Nephros secures the Standard Deviation of 2.27, risk adjusted performance of (0.08), and Mean Deviation of 1.83. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nephros, as well as the relationship between them.

Nephros Price Movement Analysis

Nephros Insider Trading Activities

Nephros Outstanding Bonds

Nephros Predictive Daily Indicators

Nephros Forecast Models

Nephros' time-series forecasting models are one of many Nephros' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Nephros' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Nephros prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Nephros shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Nephros. By using and applying Nephros Stock analysis, traders can create a robust methodology for identifying Nephros entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Nephros analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Nephros analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Nephros stock analysis indicators help investors evaluate how Nephros stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Nephros shares will generate the highest return on investment. By understating and applying Nephros stock analysis, traders can identify Nephros position entry and exit signals to maximize returns.

When running Nephros' price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.